All lobbying filings

OGR

Lobbying for LEAVITT PARTNERS, LLC ON BEHALF OF SICKLE CELL DISEASE PARTNERSHIP · consulting firm on behalf of multi-sector collaboration of health care stakeholders

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · Michigan · House · $20,000.00 income · posted Apr 19, 2026

Official filing document

Bills named in this filing 2

HR 1796
Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2025
HR 5178
Sickle Cell Disease Comprehensive Care Act

Lobbying activity 1

Health Issues

Advocating for federal health care policies based on the National Academies 2020 report that will improve the lives of patients living with Sickle Cell Disease; H.R.1796, Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act; H.R.5178, Sickle Cell Disease Comprehensive Care Act.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.